Novozymes Biopharma Offers Sodium Hyaluronate with Free Evaluation Samples
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Novozymes Biopharma, part of Novozymes, is offering customers free evaluation samples of the company's Bacillus-based sodium hyaluronate. The sample program precedes the 2011 launch of Novozymes Biopharma's new cGMP facility in Tianjin, China and will provide a opportunity to experience first-hand the quality of the product that will be manufactured at the cGMP Q7 validated site.
Novozymes Biopharma's sodium hyaluronate is 100% free of animal-derived raw materials and organic solvent remnants. The product is fermented using a non-pathogenic and well documented production strain, Bacillus subtilis, offering the medical device and pharmaceutical industries a range of benefits including increased safety, purity, batch-to-batch consistency and stability in large scale.
The company's sodium hyaluronate can be used in a wide range of applications in the pharmaceutical sector for improved drug delivery as well as in medical device application areas such as ophthalmology, dermatology, osteoarthritis, dermal fillers, adhesion prevention, coating and wound healing.
"We are delighted to offer new and existing users the opportunity to pilot Novozymes Biopharma's innovative sodium hyaluronate", comments Hans Ole Klingenberg, Product Director at Novozymes Biopharma. We are developing our new cGMP facility in China to expand the use of sodium hyaluronate and to set a new bench-mark for quality and consistency. This sample program precedes the opening of our new facility and is a unique opportunity for customers to sample our product and experience its benefits in drug delivery and medical device applications."
Novozymes Biopharma's sodium hyaluronate is 100% free of animal-derived raw materials and organic solvent remnants. The product is fermented using a non-pathogenic and well documented production strain, Bacillus subtilis, offering the medical device and pharmaceutical industries a range of benefits including increased safety, purity, batch-to-batch consistency and stability in large scale.
The company's sodium hyaluronate can be used in a wide range of applications in the pharmaceutical sector for improved drug delivery as well as in medical device application areas such as ophthalmology, dermatology, osteoarthritis, dermal fillers, adhesion prevention, coating and wound healing.
"We are delighted to offer new and existing users the opportunity to pilot Novozymes Biopharma's innovative sodium hyaluronate", comments Hans Ole Klingenberg, Product Director at Novozymes Biopharma. We are developing our new cGMP facility in China to expand the use of sodium hyaluronate and to set a new bench-mark for quality and consistency. This sample program precedes the opening of our new facility and is a unique opportunity for customers to sample our product and experience its benefits in drug delivery and medical device applications."
